Sionna Therapeutics, Inc. (SION) investor relations documents from the company's IR site: 1 presentation, 11 press releases; latest deck 2026-08-10. Read in-app with summaries. First-party data.
SION-719 Phase 2a and SION-451 Dual Combination Phase 1 Presentation: Sionna Therapeutics reports that its SION-719 Phase 2a PreciSION CF trial failed to meet its primary sweat chloride endpoint, leading to program discontinuation.
SION overview · SION earnings · SION financials · SION KPIs · SION ownership · SION peers · SION filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.